ArticleFrontiers in immunology2026
AI-derived prognostic model identifies high-risk gene signatures in pediatric gliomas.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- All-Trans Retinoic Acid and Curcumin Exhibit Hormesis or Synergistic Anticancer Effects in U87 Glioblastoma Cells: Defining the Proteome Accompanying Synergism.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pediatric gliomas, comprising both low-grade (LGGs) and high-grade gliomas (HGGs), exhibit significant molecular and clinical heterogeneity. While LGGs generally have a favorable prognosis, HGGs are associated with poor long-term survival despite aggressive treatment. Advances in molecular profiling have enabled targeted therapies, but treatment resistance and tumor heterogeneity remain major challenges. The integration of artificial intelligence (AI) and transcriptomic data holds promise for refining prognostic models and guiding personalized treatment strategies, yet its application in pediatric gliomas remains underexplored. Method: We applied the Artificial Intelligence-Derived Prognostic Index (AIDPI) model to analyze transcriptomic data from pediatric glioma patients. Differentially expressed genes (DEGs) were identified and incorporated into a machine learning-based prognostic model. Single-cell RNA-seq data were also integrated to assess cellular heterogeneity within the tumor microenvironment. Kaplan-Meier survival analysis, Cox regression, and receiver operating characteristic (ROC) curve analysis were performed to evaluate the model's predictive power. Functional enrichment analysis was conducted to explore potential therapeutic targets. Results: The AIDPI model identified nine key genes (GRIA1, ZNF165, TM9SF2, PRKAR2A, PSMD6, H1F0, CDC25B, HIST1H2AE, and NCAPD2) that were consistently associated with prognosis across multiple pediatric glioma datasets. These genes were used to construct a machine learning-based prognostic model, which demonstrated superior predictive performance with a C-index > 0.85. High AIDPI scores correlated with poorer survival outcomes, as confirmed by Kaplan-Meier survival analysis and time-dependent ROC curves. The AIDPI model outperformed 30 other glioma prognostic models, highlighting its potential for precision prognosis. Functional analysis of the AIDPI-related genes revealed involvement in immune suppression and cell adhesion pathways. Single-cell analysis identified TM9SF2 and H1F0 as key prognostic genes, with high H1F0 expression being associated with poor prognosis in pediatric gliomas. Conclusions: Our findings highlight the potential of AI-driven transcriptomic analysis in improving pediatric glioma prognosis. The identified gene signatures may serve as biomarkers for risk stratification and personalized treatment strategies, advancing precision oncology in pediatric neuro-oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.